Handelsbanken Fonder’s NewAmsterdam Pharma NAMS Stock Holding History

Handelsbanken Fonder’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.15M	Sell	122,400 -296,500	-71%	-$9.77M	0.01%	550
2026 Q1	$13.4M	Buy	418,900 +3,100	+0.7%	+$101K	0.04%	317
2025 Q4	$14.6M	Buy	415,800 +10,000	+2%	+$364K	0.04%	323
2025 Q3	$11.5M	Buy	405,800 +64,200	+19%	+$1.54M	0.04%	350
2025 Q2	$6.19M	Buy	341,600 +81,600	+31%	+$1.49M	0.02%	401
2025 Q1	$5.32M	Buy	260,000 +72,596	+39%	+$1.61M	0.02%	418
2024 Q4	$4.82M	Buy	+187,404	New	+$3.98M	0.02%	443

Other funds holding NAMS

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

MMC

Mizuho Markets Cayman Grand Cayman, Cayman Islands $2.67B AUM 103.47% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Handelsbanken Fonder's NAMS Position: Q2 2026 in Review

Handelsbanken Fonder reduced its NewAmsterdam Pharma (NAMS) stake by 71% in Q2 2026, selling an estimated $9.77M and leaving 122,400 shares worth $4.15M. The position accounts for 0.01% of the portfolio, ranked #550.

Handelsbanken Fonder first reported a position in NAMS in Q4 2024 and has held it in 7 quarters since. The position peaked at $14.6M in Q4 2025. 31 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Handelsbanken Fonder held 122,400 shares of NewAmsterdam Pharma worth $4.15M as of Q2 2026.
Handelsbanken Fonder sold 296,500 NewAmsterdam Pharma shares in Q2 2026, an estimated $9.77M.
NewAmsterdam Pharma made up 0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #550 holding.
Handelsbanken Fonder first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 7 quarters since.
Handelsbanken Fonder's NewAmsterdam Pharma position peaked at $14.6M in Q4 2025.
31 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.